<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TIH</journal-id>
<journal-id journal-id-type="hwp">sptih</journal-id>
<journal-id journal-id-type="nlm-ta">Toxicol Ind Health</journal-id>
<journal-title>Toxicology and Industrial Health</journal-title>
<issn pub-type="ppub">0748-2337</issn>
<issn pub-type="epub">1477-0393</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0748233711420473</article-id>
<article-id pub-id-type="publisher-id">10.1177_0748233711420473</article-id>
<title-group>
<article-title>Toxicity of zinc oxide nanoparticles through oral route</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Pasupuleti</surname>
<given-names>Surekha</given-names>
</name>
<xref ref-type="aff" rid="aff1-0748233711420473">1</xref>
<xref ref-type="corresp" rid="corresp1-0748233711420473"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Alapati</surname>
<given-names>Srinivas</given-names>
</name>
<xref ref-type="aff" rid="aff1-0748233711420473">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ganapathy</surname>
<given-names>Selvam</given-names>
</name>
<xref ref-type="aff" rid="aff1-0748233711420473">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Anumolu</surname>
<given-names>Goparaju</given-names>
</name>
<xref ref-type="aff" rid="aff1-0748233711420473">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pully</surname>
<given-names>Neelakanta Reddy</given-names>
</name>
<xref ref-type="aff" rid="aff2-0748233711420473">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Prakhya</surname>
<given-names>Balakrishna Murthy</given-names>
</name>
<xref ref-type="aff" rid="aff1-0748233711420473">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0748233711420473"><label>1</label>International Institute of Biotechnology and Toxicology (IIBAT), Padappai, Tamil Nadu, India</aff>
<aff id="aff2-0748233711420473"><label>2</label>Central Leather Research Institute, Adyar, Chennai, Tamil Nadu, India</aff>
<author-notes>
<corresp id="corresp1-0748233711420473">Pasupuleti Surekha, Department of Toxicology, International Institute of Biotechnology and Toxicology (IIBAT), Padappai 601301, Tamil Nadu, India Email: <email>santhoshmbt@gmail.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>28</volume>
<issue>8</issue>
<fpage>675</fpage>
<lpage>686</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>This experiment was aimed to determine the significance of dose by comparing acute oral toxicological potential of nano-sized zinc oxide (20 nm) with its micro-sized zinc oxide. Sprague Dawley rats, 8 to 9 weeks old, were administered with 5, 50, 300, 1000 and 2000 mg/kg body weight (b.w.) of nano- and micro-sized zinc oxide suspended in distilled water once through oral gavage. The effects of the micro- and nano-sized zinc oxide on biochemical and hematological parameters were analyzed on day 14 of administration. The organs were collected for histopathology. Interestingly, inverse dose-dependent increase was noted in aspartate aminotransferase, alanine aminotransferase serum levels of nano-size zinc oxide groups when compared with their micro-sized zinc oxide. Clotting time was effected in all the male groups of nano-size zinc oxide, except in 1000 mg/kg b.w. The incidences of microscopic lesions in liver, pancreas, heart and stomach were higher in lower doses of nano-size zinc oxide compared to higher dose. However, the incidences of above lesions were higher in rats treated with a high dose of micro-sized zinc oxide. We conclude that nano-size zinc oxide exhibited toxicity at lower doses, thus alarming future nanotoxicology research needs to be focused on importance of dose metrics rather following the conventional methods while conducting <italic>in vivo</italic> experiments.</p>
</abstract>
<kwd-group>
<kwd>Zinc oxide</kwd>
<kwd>nanoparticles</kwd>
<kwd>dose</kwd>
<kwd>oral</kwd>
<kwd>acute toxicity</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0748233711420473">
<title>Introduction</title>
<p>Due to the wide application of nanomaterials in industry, agriculture, business, medicine and public health nanotechnology has gained a great deal of public interest. Nanotechnology includes the integration of these nanoscale structures into larger material components and systems and construction of new and improved materials at the nanoscale (<xref ref-type="bibr" rid="bibr10-0748233711420473">Ju-Nam and Lead, 2008</xref>). Nanoscience involves research to discover new behavior and properties or materials with dimension at the nanoscale (<xref ref-type="bibr" rid="bibr21-0748233711420473">NNI, 2008</xref>). Thorough evaluation of desirable versus adverse effects is required for safe applications of engineered nanomaterials (ENMs) and major challenges lie ahead to answer the key questions of nanotoxicology (Oberdorster,<xref ref-type="bibr" rid="bibr23-0748233711420473"> 2010</xref>).</p>
<p>Since the investment in nanotechnology research and development is growing, the value of products utilizing these technologies may exceed to $3 trillion by 2015 (<xref ref-type="bibr" rid="bibr14-0748233711420473">Lux Research, 2009</xref>); hence understanding, identifying and addressing the potential risks of these novel materials to human health and the environment is of great interest (Chemical Industry Vision, 2020; <xref ref-type="bibr" rid="bibr9-0748233711420473">ICON 2008</xref>; <xref ref-type="bibr" rid="bibr13-0748233711420473">Luther, 2004</xref>; <xref ref-type="bibr" rid="bibr16-0748233711420473">Maynard, 2006</xref>; <xref ref-type="bibr" rid="bibr17-0748233711420473">Maynard et al., 2006</xref>; <xref ref-type="bibr" rid="bibr24-0748233711420473">Oberdörster et al., 2005</xref>; <xref ref-type="bibr" rid="bibr26-0748233711420473">PCAST, 2010</xref>; <xref ref-type="bibr" rid="bibr28-0748233711420473">RCEP, 2008</xref>; <xref ref-type="bibr" rid="bibr30-0748233711420473">SCENIHR, 2009</xref>, <xref ref-type="bibr" rid="bibr29-0748233711420473">2005</xref>).</p>
<p>Currently, metal oxide nanoparticles have not been comprehensively assessed in regard to the potential effects on human health, due to exposure (accidental or otherwise) in the workplace during the production of nanoparticles or exposure through use in commercial products (e.g. titanium dioxide [TiO<sub>2</sub>] or ZnO sunscreens).</p>
<p>Zinc oxide (ZnO) nanoparticles are widely used in various applications including cosmetics, paints, as drug carriers and fillings in medical materials (Dufour et al., <xref ref-type="bibr" rid="bibr4-0748233711420473">2006</xref>). These metal oxide nanoparticles can also be employed in environmental remediation due to their good absorptive and photocatalytic properties for elimination or degradation of pollutants in water or air (Qiang, <xref ref-type="bibr" rid="bibr27-0748233711420473">2001</xref>). In addition, photocatalytic studies indicated that these nanomaterials showed good photocatalytic performance for organic pollutants in water (<xref ref-type="bibr" rid="bibr34-0748233711420473">Wu and Huanga, 2010</xref>).</p>
<p>In spite of the fact that ZnO is a widely used ingredient in dermatological preparations and sunscreens and many other products, only two investigations have focused on the effects of these nanoparticles through oral administration on mice and through dietary exposure on snails (Croteau<xref ref-type="bibr" rid="bibr3-0748233711420473"> et al., 2011</xref>; Wang<xref ref-type="bibr" rid="bibr32-0748233711420473"> et al., 2008</xref>).</p>
<p>Although many studies aimed to understand the importance of physicochemical properties such as size, surface area, crystal structure, agglomerating property and surface charge in influencing the biological activity (<xref ref-type="bibr" rid="bibr6-0748233711420473">Hoet et al., 1999</xref>, <xref ref-type="bibr" rid="bibr7-0748233711420473">2001</xref>; Hoshino et al., <xref ref-type="bibr" rid="bibr8-0748233711420473">2004</xref>; Magrez<xref ref-type="bibr" rid="bibr15-0748233711420473"> et al., 2006</xref>; Nel<xref ref-type="bibr" rid="bibr20-0748233711420473"> et al., 2006</xref>; <xref ref-type="bibr" rid="bibr25-0748233711420473">Oberdorster et al., 2005</xref>; Wick<xref ref-type="bibr" rid="bibr33-0748233711420473"> et al., 2007</xref>), the use of appropriate dose metric needs to be carefully considered. Keeping in mind the uncertainity in dose selection, we have made an attempt to understand the importance of dose by comparing nano-size ZnO with its micro-size counterpart at different dose levels.</p>
</sec>
<sec id="section2-0748233711420473" sec-type="materials|methods">
<title>Materials and methods</title>
<p>ZnO nanoparticles (Stock No. 5810HT) were purchased from Nanostructured and Amorphous Materials, Inc. USA. The ZnO (Product No. ZO385) was purchased from Sigma Aldrich, USA.</p>
<sec id="section3-0748233711420473">
<title>Physicochemical characterization</title>
<p>ZnO nanoparticles were synthesized by wet chemistry method. The manufacturer specifications for nanomaterial characterization were confirmed by the following techniques. The characteristics of ZnO nanoparticles were assessed in the as-synthesized form prior to use in experiments or after dispersion in the vehicle (water) for dosing. Solution (water) characteristics were measured with dynamic light scattering (DLS), at Malvern Aimil Ltd, Bangalore. The size of nano-size ZnO was determined with scanning electron microscopy (SEM), at Anna University, Chennai. SEM produces images by rastering a primary electron beam across the sample surface while detecting secondary or backscattered electrons, which are emitted from the surface. Therefore, the images obtained in an SEM provide a 3D quality and greater resolution. In this study, Hitachi S-520 SEM was used at an accelerating voltage of 10,000 V after depositing the samples onto aluminum stubs with double-sided carbon adhesive tape. Photon correlation spectroscopy or DLS is an analytical technique capable of measuring the size of very small particles, at low sample concentrations. Measurement of particle size of nano ZnO in solution was determined with DLS on a Malvern Zetasizer nanoseries (Nano ZS) with Malvern application software version 6.20. This instrument can measure particle sizes ranging from 0.6 nm to 6 μm using noninvasive back scatter (NIBS) technology and DLS. The Malvern Zetasizer can also provide zeta potential measurements in aqueous and nonaqueous dispersions using M3-phase analysis light scattering (PALS) technology. Zeta potential is defined as the accumulation of charge around the surface of a particle in solution and gives an indication of the stability of the colloidal system.</p>
</sec>
<sec id="section4-0748233711420473">
<title>Animals and housing conditions</title>
<p>Experimental animals were obtained from in-house animal facility. All procedures using animals were reviewed and approved by the institutional animal ethics committee.</p>
</sec>
<sec id="section5-0748233711420473">
<title>Acute oral toxicity test in rats</title>
<p>Acute oral toxicity—acute toxic class method was conducted per the Organization for Economic Co-operation and Development (OECD) 423 guidelines (OECD, 2001) with modifications in terms of different dose levels, usage of sexes, animal number, and inclusion of hematology, biochemical parameters and histopathology evaluation. The healthy Sprague Dawley rats of both sex, aged between 8 and 9 weeks and body weights of 180–220 g were used. Females were nulliparous and nonpregnant. The animals were procured from breeding facilities of International Institute of Biotechnology and Toxicology (IIBAT). Animals were housed in polypropylene cages with stainless steel grills and gamma-irradiated corn cobs were used as bedding. Bedding material, cages, grills and water bottles were changed on alternate days. Animals were housed individually sex wise and group wise. Animals were acclimated for a minimum period of 5 days in the controlled environment (temperature: 22 ± 3°C; relative humidity: 50 ± 20% and light: 12-h light/dark cycle) and <italic>ad libitum</italic> supply of reverse osmosis water and a standard rodent pellet feed (supplier: M/s. Tetragon Chemie Pvt. Ltd, Bangalore, India). Feed alone was withdrawn overnight prior to the dosing and following dosing, for a period of 3 hours.</p>
<p>One hundred and ten animals were distributed randomly into different groups (<xref ref-type="table" rid="table1-0748233711420473">Table 1</xref>).</p>
<table-wrap id="table1-0748233711420473" position="float">
<label>Table 1.</label>
<caption>
<p>Groups and dose levels of micro- and nano-size zinc oxide</p>
</caption>
<graphic alternate-form-of="table1-0748233711420473" xlink:href="10.1177_0748233711420473-table1.tif"/>
<table>
<thead>
<tr>
<th>Group</th>
<th>Dose</th>
<th>No. of animals</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="3">Micro-size zinc oxide</td>
</tr>
<tr>
<td> G1</td>
<td>Vehicle control</td>
<td>5 Males and 5 females</td>
</tr>
<tr>
<td> G2 (M-5)</td>
<td>5 mg/kg b.w.</td>
<td>5 Males and 5 females</td>
</tr>
<tr>
<td> G3 (M-50)</td>
<td>50 mg/kg b.w.</td>
<td>5 Males and 5 females</td>
</tr>
<tr>
<td> G4 (M-300)</td>
<td>300 mg/kg b.w.</td>
<td>5 Males and 5 females</td>
</tr>
<tr>
<td> G5 (M-1000)</td>
<td>1000 mg/kg b.w.</td>
<td>5 Males and 5 females</td>
</tr>
<tr>
<td> G6 (M-2000)</td>
<td>2000 mg/kg b.w.</td>
<td>5 Males and 5 females</td>
</tr>
<tr>
<td colspan="3">Nano-size zinc oxide</td>
</tr>
<tr>
<td> G7 (N-5)</td>
<td>5 mg/kg b.w.</td>
<td>5 Males and 5 females</td>
</tr>
<tr>
<td> G8 (N-50)</td>
<td>50 mg/kg b.w.</td>
<td>5 Males and 5 females</td>
</tr>
<tr>
<td> G9 (N-300)</td>
<td>300 mg/kg b.w.</td>
<td>5 Males and 5 females</td>
</tr>
<tr>
<td> G10 (N-1000)</td>
<td>1000 mg/kg b.w.</td>
<td>5 Males and 5 females</td>
</tr>
<tr>
<td> G11 (N-2000)</td>
<td>2000 mg/kg b.w.</td>
<td>5 Males and 5 females</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>The test materials (either micro-size ZnO or nano-size ZnO) were suspended in distilled water and administered through oral gavage once at dose levels of 5, 50, 300, 1000 and 2000 mg/kg body weight (b.w.). The test solution was prepared shortly prior to the administration. The dose volume maintained for all the groups was maximum (10 ml/kg b.w.). Similarly, control group of animals (5 males and 5 females) were dosed with distilled water alone. Animals were observed for mortality/morbidity, clinical signs of toxicity, weekly body weight and weekly food consumption during the experimental period.</p>
<p>At the end of 14 days of administration, the animals were killed and the blood was obtained through ophthalmic vein. The organs such as esophagus, stomach, small and large intestines, liver, spleen, thymus, mandibular and mesenteric lymphnodes, kidney, urinary bladder, heart, pancreas, brain, lungs ovaries and testes were collected, and all the organs were kept in 10% buffered formalin and the testes in modified Davidson fluid.</p>
</sec>
<sec id="section6-0748233711420473">
<title>Clinical biochemistry</title>
<p>The serum obtained after centrifuging was analyzed for biochemical parameters such as creatinine, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), amylase, aspartate aminotransferase (AST), blood urea nitrogen (BUN), calcium, cholinesterase, total cholesterol, glucose, HDL cholesterol, iron, phosphorus, total protein, triglycerides, urea and zinc using Humastar 300 fully automated biochemistry analyzer (Human GmbH., Germany), and sodium, potassium and chlorides in serum were analyzed on day 14 by means of a humalyte electrolyte analyzer (Human GmbH., Germany).</p>
</sec>
<sec id="section7-0748233711420473">
<title>Hematology</title>
<p>Blood treated with EDTA was used for analyzing hematology parameters such as erythrocyte count (red blood cell [RBC]), hemoglobin, hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), platelet (PLT) count, total leucocyte count (white blood cell [WBC]) and differential count (five parameters namely neutrophils, eosinophils, basophils, lymphocytes and monocytes) were determined on day 14 using Bayer ADVIA 120, fully automated hematology analyzer (Bayer, Germany). Clotting time of blood was determined by capillary tube method.</p>
</sec>
<sec id="section8-0748233711420473">
<title>Necropsy</title>
<p>Gross pathology was performed at the end of experimental period (day 14).</p>
</sec>
<sec id="section9-0748233711420473">
<title>Histopathology</title>
<p>Histopathology of organs (liver, spleen, kidneys, heart, adrenals, lungs, pancreas, stomach, esophagus, small and large intestine) were evaluated. Tissues were collected and preserved in 10% buffered formalin. All tissues required for histopathology evaluation were subjected to dehydration procedure and processed in tissue processor, embedded in paraffin wax and prepared sections of 5–8 μm thickness and stained with hematoxylin-eosin stain.</p>
</sec>
<sec id="section10-0748233711420473">
<title>Statistical analysis</title>
<p>The data was expressed as mean +/− standard deviation for statistical analysis. A comparison of treated rats with control groups was done using Newman–Keuls multiple comparison test. The data found to be heterogeneous were subjected to nonparametricKruskal–Wallis multiple comparison <italic>Z</italic> value test. The comparison of nano- and micro-size ZnO dose groups were done by Student’s <italic>t</italic> test and the heterogenous data subjected to Mann–Whitney <italic>U</italic> test. The alpha level at which all tests were conducted is 0.05, and the NCSS 2007 software was used for analysis.</p>
</sec>
</sec>
<sec id="section11-0748233711420473">
<title>Results</title>
<sec id="section12-0748233711420473">
<title>Physicochemical characterization</title>
<p>The average size of the nano ZnO is 63 nm in SEM analysis (<xref ref-type="fig" rid="fig1-0748233711420473">Figure 1</xref>). The properties of the solution of nanomaterials in distilled water were examined for changes in size due to agglomeration using DLS (Dufour<xref ref-type="bibr" rid="bibr4-0748233711420473"> et al., 2006</xref>). Average size was calculated by the software from the intensity, volume and number distributions measured (<xref ref-type="table" rid="table2-0748233711420473">Table 2</xref>). The DLS results illustrate that depending on the material, the nanomaterials in solution do not necessarily retain their nano size (Dufour<xref ref-type="bibr" rid="bibr4-0748233711420473"> et al., 2006</xref>). The average size of nano ZnO (in solution) was 224.7 nm. The polydispersity index was 0.305. The zeta potential of nano-size ZnO was −30.9 mV (<xref ref-type="table" rid="table2-0748233711420473">Table 2</xref>).</p>
<fig id="fig1-0748233711420473" position="float">
<label>Figure 1.</label>
<caption>
<p>Scanning electron microscopic (SEM) image of nano zinc oxide.</p>
</caption>
<graphic xlink:href="10.1177_0748233711420473-fig1.tif"/>
</fig>
<table-wrap id="table2-0748233711420473" position="float">
<label>Table 2.</label>
<caption>
<p>Nano zinc oxide characterization</p>
</caption>
<graphic alternate-form-of="table2-0748233711420473" xlink:href="10.1177_0748233711420473-table2.tif"/>
<table>
<thead>
<tr>
<th>Average size<sup>
<xref ref-type="table-fn" rid="table-fn2-0748233711420473">a</xref>
</sup>
</th>
<th>Size using SEM</th>
<th>Size in distilled water<sup>
<xref ref-type="table-fn" rid="table-fn3-0748233711420473">b</xref>
</sup>
</th>
<th>Polydispersity index</th>
<th>Surface area<sup>
<xref ref-type="table-fn" rid="table-fn4-0748233711420473">c</xref>
</sup> (m<sup>2</sup>/g)</th>
<th>Zeta potential<sup>
<xref ref-type="table-fn" rid="table-fn5-0748233711420473">d</xref>
</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 nm</td>
<td>63 nm</td>
<td>224.7 nm</td>
<td>0.305</td>
<td>50</td>
<td>−30.9</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0748233711420473">
<p>SEM: scanning electron microscopy.</p>
</fn>
</table-wrap-foot>
<table-wrap-foot>
<fn id="table-fn2-0748233711420473">
<p>
<sup>a</sup>According to the manufacturer.</p>
</fn>
</table-wrap-foot>
<table-wrap-foot>
<fn id="table-fn3-0748233711420473">
<p>
<sup>b</sup>Using dynamic light scattering (DLS).</p>
</fn>
<fn id="table-fn4-0748233711420473">
<p>
<sup>c</sup>Using BET (Brunauer, Emmett, Teller) analysis.</p>
</fn>
<fn id="table-fn5-0748233711420473">
<p>
<sup>d</sup>Using zeta sizer.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section13-0748233711420473">
<title>Clinical biochemistry</title>
<p>The effects of micro-size and nano-size ZnO on rats are presented in <xref ref-type="table" rid="table3-0748233711420473">Table 3</xref>. The results indicated that the plasma ALT and AST of nano-ZnO-treated rats were significantly higher than the controls and with the micro-size counterparts in both the sexes. There is an inverse dose-dependent increase in the AST and ALT serum levels in animals treated with nano-size ZnO compared with their micro-size counterparts (<xref ref-type="fig" rid="fig2-0748233711420473">Figures 2</xref>
<xref ref-type="fig" rid="fig3-0748233711420473"/>
<xref ref-type="fig" rid="fig4-0748233711420473"/>–<xref ref-type="fig" rid="fig5-0748233711420473">5</xref>). Calcium levels in the serum were also significantly high from control as well as with the micro-size ZnO-treated groups in males. Females have no difference in the calcium levels. However, there are no significant differences in rest of the parameters analyzed (<xref ref-type="table" rid="table3-0748233711420473">Table 3</xref>; <xref ref-type="fig" rid="fig6-0748233711420473">Figure 6</xref>).</p>
<fig id="fig2-0748233711420473" position="float">
<label>Figure 2.</label>
<caption>
<p>Alanine aminotransferase (ALT) activity in males treated with nano zinc oxide at different dose levels (mg/kg body weight [b.w.]).</p>
</caption>
<graphic xlink:href="10.1177_0748233711420473-fig2.tif"/>
</fig>
<fig id="fig3-0748233711420473" position="float">
<label>Figure 3.</label>
<caption>
<p>Alanine aminotransferase (ALT) activity in females treated with nano zinc oxide at different dose levels (mg/kg body weight [b.w.]).</p>
</caption>
<graphic xlink:href="10.1177_0748233711420473-fig3.tif"/>
</fig>
<fig id="fig4-0748233711420473" position="float">
<label>Figure 4.</label>
<caption>
<p>Aspartate aminotransferase (AST) activity in males treated with nano zinc oxide at different dose levels (mg/kg body weight [b.w.]).</p>
</caption>
<graphic xlink:href="10.1177_0748233711420473-fig4.tif"/>
</fig>
<fig id="fig5-0748233711420473" position="float">
<label>Figure 5.</label>
<caption>
<p>Aspartate aminotransferase (AST) activity in females treated with nano zinc oxide at different dose levels (mg/kg body weight [b.w.]).</p>
</caption>
<graphic xlink:href="10.1177_0748233711420473-fig5.tif"/>
</fig>
<fig id="fig6-0748233711420473" position="float">
<label>Figure 6.</label>
<caption>
<p>Calcium levels in males treated with nano zinc oxide at different dose levels (mg/kg body weight [b.w.]).</p>
</caption>
<graphic xlink:href="10.1177_0748233711420473-fig6.tif"/>
</fig>
<table-wrap id="table3-0748233711420473" position="float">
<label>Table 3.</label>
<caption>
<p>Clinical biochemistry parameters (males and females)</p>
</caption>
<graphic alternate-form-of="table3-0748233711420473" xlink:href="10.1177_0748233711420473-table3.tif"/>
<table>
<thead>
<tr>
<th>Group</th>
<th>ALT</th>
<th>AST</th>
<th>Ca</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="4">Males</td>
</tr>
<tr>
<td> G1</td>
<td>65.0 ± 14.1</td>
<td>141 ± 16.6</td>
<td>8.0 ± 0.6</td>
</tr>
<tr>
<td> G2 (M-5)</td>
<td>83.2 ± 12.9</td>
<td>129.2 ± 9.0</td>
<td>8.0 ± 0.6</td>
</tr>
<tr>
<td> G3 (M-50)</td>
<td>71.0 ± 13.6</td>
<td>135.6 ± 6.3</td>
<td>8.4 ± 0.7</td>
</tr>
<tr>
<td> G4 (M-300)</td>
<td>72.8 ± 19.8</td>
<td>139.8 ± 11.6</td>
<td>9.1 ± 0.3</td>
</tr>
<tr>
<td> G5 (M-1000)</td>
<td>80.0 ± 14.8</td>
<td>135.6 ± 11.0</td>
<td>8.8 ± 0.6</td>
</tr>
<tr>
<td> G6 (M-2000)</td>
<td>73.0 ± 14.0</td>
<td>151.8 ± 6.9</td>
<td>8.3 ± 0.5</td>
</tr>
<tr>
<td> G7 (N-5)</td>
<td>747.0 ± 120.6<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>687.4 ± 83.1<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>10.1 ± 0.1<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
</tr>
<tr>
<td> G8 (N-50)</td>
<td>514 ± 88.0<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>553.6 ± 55.5<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>10.3 ± 0.2<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
</tr>
<tr>
<td> G9 (N-300)</td>
<td>428.6 ± 111.5<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>509.6 ± 41.5<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>10.6 ± 0.4<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
</tr>
<tr>
<td> G10 (N-1000)</td>
<td>395.2 ± 57.8<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>411.8 ± 66.6<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>10.2 ± 0.2<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
</tr>
<tr>
<td> G11 (N-2000)</td>
<td>298.4 ± 119.1<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>357.4 ± 69.3<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>10.1 ± 0.1<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
</tr>
<tr>
<td colspan="4">Females</td>
</tr>
<tr>
<td> G1</td>
<td>68.6 ± 12.2</td>
<td>150.6 ± 11.5</td>
<td>9.2 ± 0.6</td>
</tr>
<tr>
<td> G2 (M-5)</td>
<td>78.6 ± 8.4</td>
<td>152.8 ± 10.7</td>
<td>9.6 ± 0.8</td>
</tr>
<tr>
<td> G3 (M-50)</td>
<td>71.8 ± 8.8</td>
<td>152.2 ± 12.0</td>
<td>9.2 ± 0.8</td>
</tr>
<tr>
<td> G4 (M-300)</td>
<td>79.2 ± 6.4</td>
<td>157.4 ± 9.1</td>
<td>9.4 ± 0.8</td>
</tr>
<tr>
<td> G5 (M-1000)</td>
<td>79.2 ± 6.4</td>
<td>157.4 ± 9.1</td>
<td>9.4 ± 0.8</td>
</tr>
<tr>
<td> G6 (M-2000)</td>
<td>76.0 ± 15.0</td>
<td>140.8 ± 12.4</td>
<td>9.7 ± 0.6</td>
</tr>
<tr>
<td> G7 (N-5)</td>
<td>712.2 ± 169.5<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>501.6 ± 49.3<sup>
<xref ref-type="table-fn" rid="table-fn7-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn8-0748233711420473">b</xref>
</sup>
</td>
<td>10.0 ± 0.3</td>
</tr>
<tr>
<td> G8 (N-50)</td>
<td>521.4 ± 39.8<sup>a,b</sup>
</td>
<td>404.8 ± 86.7<sup>a,b</sup>
</td>
<td>9.6 ± 0.8</td>
</tr>
<tr>
<td> G9 (N-300)</td>
<td>464.2 ± 61.2<sup>a,b</sup>
</td>
<td>345.8 ± 50.1</td>
<td>9.6 ± 0.7</td>
</tr>
<tr>
<td> G10 (N-1000)</td>
<td>355.6 ± 106.6<sup>a,b</sup>
</td>
<td>276.6 ± 47.6<sup>a,b</sup>
</td>
<td>10.2 ± 0.8</td>
</tr>
<tr>
<td> G11 (N-2000)</td>
<td>248.6 ± 126.4<sup>a,b</sup>
</td>
<td>226.8 ± 18.8<sup>a,b</sup>
</td>
<td>10.0 ± 0.4</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn6-0748233711420473">
<p>ALP: alkaline phosphatase, ALT: alanine transaminase, AST: aspartate transaminase, Ca: calcium.</p>
</fn>
<fn id="table-fn7-0748233711420473">
<p>
<sup>a</sup>Statistically different from control; <italic>p</italic> &lt; 0.05 (<italic>n</italic> = 5); mean +/− standard deviation.</p>
</fn>
<fn id="table-fn8-0748233711420473">
<p>
<sup>b</sup>Statistically different from micro-size dose group; <italic>p</italic> &lt; 0.05 (<italic>n</italic> = 5); mean +/− standard deviation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section14-0748233711420473">
<title>Hematology</title>
<p>There were no statistically significant changes in the hematologic parameters when compared to control. Although few parameters such as PLT, HCT and MCV are statistically different from their micro-size counterparts, the values are within the historical range of the institute. A statistically significant increase in clotting time was observed in all the treatment groups of nano-size ZnO with that of micro-size ZnO dose groups except group 10 ([G10] 1000 mg/kg b.w.; <xref ref-type="table" rid="table4-0748233711420473">Table 4</xref>; <xref ref-type="fig" rid="fig7-0748233711420473">Figure 7</xref>).</p>
<fig id="fig7-0748233711420473" position="float">
<label>Figure 7.</label>
<caption>
<p>Clotting time in males treated with nano zinc oxide at different dose levels (mg/kg body weight [b.w.]).</p>
</caption>
<graphic xlink:href="10.1177_0748233711420473-fig7.tif"/>
</fig>
<table-wrap id="table4-0748233711420473" position="float">
<label>Table 4.</label>
<caption>
<p>Hematology parameters—males</p>
</caption>
<graphic alternate-form-of="table4-0748233711420473" xlink:href="10.1177_0748233711420473-table4.tif"/>
<table>
<thead>
<tr>
<th>Group</th>
<th>Clotting time (sec)</th>
</tr>
</thead>
<tbody>
<tr>
<td>G1 (control)</td>
<td>83.20 ± 9.71</td>
</tr>
<tr>
<td>G2 (M-5)</td>
<td>107.20 ± 9.98</td>
</tr>
<tr>
<td>G3 (M-50)</td>
<td>111.40 ± 12.82</td>
</tr>
<tr>
<td>G4 (M-300)</td>
<td>105.40 ± 26.47</td>
</tr>
<tr>
<td>G5 (M-1000)</td>
<td>129.60 ± 4.16</td>
</tr>
<tr>
<td>G6 (M-2000)</td>
<td>97.00 ± 35.19</td>
</tr>
<tr>
<td>G7 (N-5)</td>
<td>127.60 ± 8.26<sup>
<xref ref-type="table-fn" rid="table-fn9-0748233711420473">a</xref>
</sup>
</td>
</tr>
<tr>
<td>G8 (N-50)</td>
<td>144.80 ± 20.91<sup>
<xref ref-type="table-fn" rid="table-fn9-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn10-0748233711420473">b</xref>
</sup>
</td>
</tr>
<tr>
<td>G9 (N-300)</td>
<td>115.20 ± 14.02<sup>
<xref ref-type="table-fn" rid="table-fn9-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn10-0748233711420473">b</xref>
</sup>
</td>
</tr>
<tr>
<td>G10 (N-1000)</td>
<td>81.60 ± 31.33</td>
</tr>
<tr>
<td>G11 (N-2000)</td>
<td>124.80 ± 22.93<sup>
<xref ref-type="table-fn" rid="table-fn9-0748233711420473">a</xref>,<xref ref-type="table-fn" rid="table-fn10-0748233711420473">b</xref>
</sup>
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0748233711420473">
<p>
<sup>a</sup> Statistically different from control <italic>p </italic>&lt; 0.05 (<italic>n</italic> = 5); ± standard deviation.</p>
</fn>
<fn id="table-fn10-0748233711420473">
<p>
<sup>b</sup> Statistically different from micro-size dose group<italic> p </italic>&lt; 0.05 (<italic>n</italic> = 5); ± standard deviation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section15-0748233711420473">
<title>Necropsy</title>
<p>No gross pathological lesions were observed in any of the treatment groups.</p>
</sec>
<sec id="section16-0748233711420473">
<title>Histopathology</title>
<p>Animals treated with nano- and micro-size ZnO showed lesions in liver and pancreas. In addition to this, animals treated with nano-size ZnO at 2000, 1000, 300, 50 and 5 mg/kg b.w. showed lesions in stomach and heart as well (<xref ref-type="fig" rid="fig8-0748233711420473">Figures 8</xref>
<xref ref-type="fig" rid="fig9-0748233711420473"/>
<xref ref-type="fig" rid="fig10-0748233711420473"/>–<xref ref-type="fig" rid="fig11-0748233711420473">11</xref>). No lesions were observed in the similar treatment groups of micro-size ZnO (<xref ref-type="table" rid="table5-0748233711420473">Tables 5</xref> and <xref ref-type="table" rid="table6-0748233711420473">6</xref>).</p>
<fig id="fig8-0748233711420473" position="float">
<label>Figure 8.</label>
<caption>
<p>(a) Normal structure of liver of control group. Degeneration of liver treated (b) with micro-size zinc oxide at dose of 2000 mg/kg body weight (b.w.) and (c) with nano zinc oxide at dose of 2000 mg/kg b.w. Focal necrosis of liver treated with (d) micro zinc oxide at a dose of 2000 mg/kg b.w. and (e) nano zinc oxide at a dose of 2000 mg/kg b.w. (×20).</p>
</caption>
<graphic xlink:href="10.1177_0748233711420473-fig8.tif"/>
</fig>
<fig id="fig9-0748233711420473" position="float">
<label>Figure 9.</label>
<caption>
<p>(a) Normal architecture of pancreas of control group. Inflammatory cell infiltration treated (b) with micro-size zinc oxide at a dose of 2000 mg/kg body weight (b.w.) and (c) with nano-size zinc oxide at a dose of 2000 mg/kg b.w. (×20).</p>
</caption>
<graphic xlink:href="10.1177_0748233711420473-fig9.tif"/>
</fig>
<fig id="fig10-0748233711420473" position="float">
<label>Figure 10.</label>
<caption>
<p>(a) Normal structure of stomach in control group. (b) Inflammatory cell infiltration, polymorphs treated with nano-size zinc oxide at a dose of 5 mg/kg body weight [b.w.] ×20).</p>
</caption>
<graphic xlink:href="10.1177_0748233711420473-fig10.tif"/>
</fig>
<fig id="fig11-0748233711420473" position="float">
<label>Figure 11.</label>
<caption>
<p>(a) Normal structure of heart in control group. (b) Inflammatory cell of heart at a dose of 5 mg/kg body weight ([b.w.] nano-sized zinc oxide; ×20).</p>
</caption>
<graphic xlink:href="10.1177_0748233711420473-fig11.tif"/>
</fig>
<table-wrap id="table5-0748233711420473" position="float">
<label>Table 5.</label>
<caption>
<p>Histopathology lesions of target organs</p>
</caption>
<graphic alternate-form-of="table5-0748233711420473" xlink:href="10.1177_0748233711420473-table5.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Dose/group</th>
<th rowspan="2">Organ</th>
<th rowspan="2">Lesions</th>
<th colspan="2">Incidence</th>
</tr>
<tr>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>–</td>
<td>–</td>
<td align="center">–</td>
<td align="center">–</td>
</tr>
<tr>
<td rowspan="2">G6 (M-2000)</td>
<td>Liver</td>
<td>Focal necrosis, inflammatory cell foci, degeneration</td>
<td>4/5</td>
<td>3/5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Inflammatory cell infiltration</td>
<td>3/5</td>
<td>1/5</td>
</tr>
<tr>
<td rowspan="4">G7 (N-5)</td>
<td>Liver</td>
<td>Focal necrosis, degeneration, inflammatory cell foci</td>
<td>5/5</td>
<td>4/5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Inflammatory cell infiltration</td>
<td>4/5</td>
<td>3/5</td>
</tr>
<tr>
<td>Stomach</td>
<td>Inflammatory cell foci, polymorphs</td>
<td>3/5</td>
<td>2/5</td>
</tr>
<tr>
<td>Heart</td>
<td>Inflammatory cell infiltration</td>
<td>4/5</td>
<td>2/5</td>
</tr>
<tr>
<td rowspan="4">G8 (N-50)</td>
<td>Liver</td>
<td>Focal necrosis, degeneration, inflammatory cell foci</td>
<td>4/5</td>
<td>4/5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Inflammatory cell infiltration</td>
<td>3/5</td>
<td>4/5</td>
</tr>
<tr>
<td>Stomach</td>
<td>Inflammatory cell foci, polymorphs</td>
<td>2/5</td>
<td>1/5</td>
</tr>
<tr>
<td>Heart</td>
<td>Inflammatory cell infiltration</td>
<td>3/5</td>
<td>2/5</td>
</tr>
<tr>
<td rowspan="4">G9 (N-300)</td>
<td>Liver</td>
<td>Focal necrosis, inflammatory cell foci</td>
<td>4/5</td>
<td>2/5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Inflammatory cell infiltration</td>
<td>3/5</td>
<td>2/5</td>
</tr>
<tr>
<td>Stomach</td>
<td>Inflammatory cell foci, polymorphs</td>
<td>2/5</td>
<td>0/5</td>
</tr>
<tr>
<td>Heart</td>
<td>Inflammatory cell infiltration</td>
<td>2/5</td>
<td>1/5</td>
</tr>
<tr>
<td rowspan="4">G10 (N-1000)</td>
<td>Liver</td>
<td>Focal necrosis, inflammatory cell foci</td>
<td>4/5</td>
<td>3/5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Inflammatory cell infiltration</td>
<td>3/5</td>
<td>3/5</td>
</tr>
<tr>
<td>Stomach</td>
<td>Inflammatory cell foci, polymorphs</td>
<td>2/5</td>
<td>1/5</td>
</tr>
<tr>
<td>Heart</td>
<td>Inflammatory cell infiltration</td>
<td>2/5</td>
<td>0/5</td>
</tr>
<tr>
<td rowspan="3">G11 (N-2000)</td>
<td>Liver</td>
<td>Focal necrosis, inflammatory cell foci</td>
<td>4/5</td>
<td>2/5</td>
</tr>
<tr>
<td>Pancreas</td>
<td>Inflammatory cell infiltration</td>
<td>4/5</td>
<td>2/5</td>
</tr>
<tr>
<td>Stomach</td>
<td>Inflammatory cell foci, polymorphs</td>
<td>2/5</td>
<td>0/5</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="table6-0748233711420473" position="float">
<label>Table 6.</label>
<caption>
<p>Incidence of histopathology lesions</p>
</caption>
<graphic alternate-form-of="table6-0748233711420473" xlink:href="10.1177_0748233711420473-table6.tif"/>
<table>
<thead>
<tr>
<th>Group</th>
<th>Liver<sup>
<xref ref-type="table-fn" rid="table-fn11-0748233711420473">a</xref>
</sup> severity/incidence</th>
<th>Pancreas<sup>
<xref ref-type="table-fn" rid="table-fn12-0748233711420473">b</xref>
</sup> severity/incidence</th>
<th>Stomach<sup>
<xref ref-type="table-fn" rid="table-fn13-0748233711420473">c</xref>
</sup> severity/incidence</th>
<th>Heart<sup>
<xref ref-type="table-fn" rid="table-fn14-0748233711420473">d</xref>
</sup> severity/incidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>G6 (M-2000)</td>
<td>++/7<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
<td>+/4<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>G7 (N-5)</td>
<td>++/9<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
<td>++/7<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
<td>+/5<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
<td>++/6<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
</tr>
<tr>
<td>G8 (N-50)</td>
<td>++/8<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
<td>++/7<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
<td>+/3<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
<td>++/5<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
</tr>
<tr>
<td>G9 (N-300)</td>
<td>++/6<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
<td>+/5<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
<td>+/2<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
<td>+/3<sup>
<xref ref-type="table-fn" rid="table-fn15-0748233711420473">e</xref>
</sup>
</td>
</tr>
<tr>
<td>G10 (N-1000)</td>
<td>++/7<sup>e</sup>
</td>
<td>+/6<sup>e</sup>
</td>
<td>+/3<sup>e</sup>
</td>
<td>+/2<sup>e</sup>
</td>
</tr>
<tr>
<td>G11 (N-2000)</td>
<td>++/6<sup>e</sup>
</td>
<td>+/6<sup>e</sup>
</td>
<td>+/2<sup>e</sup>
</td>
<td>–</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0748233711420473">
<p>
<sup>a</sup>Focal and single-cell necrosis, degeneration, fibrous scar and inflammatory cell foci.</p>
</fn>
<fn id="table-fn12-0748233711420473">
<p>
<sup>b</sup>Inflammatory cell infiltration.</p>
</fn>
<fn id="table-fn13-0748233711420473">
<p>
<sup>c</sup>Inflammatory cell infiltration and polymorphs.</p>
</fn>
<fn id="table-fn14-0748233711420473">
<p>
<sup>d</sup>Inflammatory cell infiltration.</p>
</fn>
<fn id="table-fn15-0748233711420473">
<p>
<sup>e</sup>Incidence observed in 10 animals/group (both sexes).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
<sec id="section17-0748233711420473">
<title>Discussion</title>
<p>The current study investigated the toxicity response of nano-size ZnO at different dose levels in Sprague Dawley rats in comparison with their micro-size ZnO counterparts. Although <xref ref-type="bibr" rid="bibr32-0748233711420473">Wang et al. (2008</xref>) has conducted studies on oral toxicity of nano-size ZnO (20 and 120 nm) and zinc powder in mice, they concluded that future research needs to focus on the toxicity induced by exposure to low oral dose of small-sized (20-nm) ZnO. We have conducted the study with lowest dose ranging from 5 mg/kg b.w. to the highest dose of 2000 mg/kg b.w.</p>
<p>A significant increase in the AST and ALT levels was recorded in all the dose groups treated with of nano-size ZnO (5–2000 mg/kg b.w. [N-5–N-2000]). There was an inverse dose-dependent response suggesting that the damage to liver is high in the low-dose (5 mg/kg b.w.) group when compared to the high-dose group (2000 mg/kg b.w.). AST and ALT are the two liver enzymes whose serum level gets elevated during necrosis, degeneration, hepatitis and inflammatory condition (<xref ref-type="bibr" rid="bibr5-0748233711420473">Ellis et al., 1978</xref>; <xref ref-type="bibr" rid="bibr11-0748233711420473">Kellerman, 1995</xref>). The incidence of histopathology lesions of liver correlated with the elevated liver enzyme levels. Surekha et al. (in press) have reported the inverse dose response of nano-size ZnO through dermal route. There is no change in AST and ALT levels in any of the groups treated with micro ZnO (5–2000 mg/kg b.w. [M-5–M-2000]). This may be due to their large size. The nano-size ZnO at all the dose levels has raised the above enzyme levels depicting severe liver damage at the lowest dose levels, thus suggesting the importance of particle number concentration rather than conventional mass concentration dose metrics. In contradictory to our findings, previous studies (<xref ref-type="bibr" rid="bibr18-0748233711420473">Maynard and Kuempel, 2005</xref>; <xref ref-type="bibr" rid="bibr22-0748233711420473">Oberdörster, 2000</xref>) through inhalation route have suggested particle surface area as relevant metric for small insoluble particles instead of mass concentration which may not necessarily be applicable to the oral route.</p>
<p>
<xref ref-type="bibr" rid="bibr32-0748233711420473">Wang et al. (2008</xref>) reported inflammatory cell infiltration in pancreas at higher dose level (5 g/kg b.w.) with 120 nm size ZnO powder in CD-ICR mice. Although similar pancreatic lesion was observed in the high dose (6 of 10), the incidence of the lesions was higher in the lower dose (7 of 10) level (5 mg/kg b.w.). Histopathology evaluation of heart and stomach revealed inflammatory cell infiltration in higher incidence at lower dose (5 mg/kg b.w.) group when compared to the higher dose (2000 mg/kg b.w.). The inflammation may be due to the generation of free radicals by the metal oxide nanoparticles which leads to oxidative stress (<xref ref-type="bibr" rid="bibr12-0748233711420473">Kreyling et al., 2006</xref>).</p>
<p>Although there is increase in clotting time in males of all the groups treated with nano-size ZnO except in G10 (N-1000) the increase is not dose- and sex-dependent. The increase in clotting time may be due to decreased synthesis of proteins involved in the coagulation cascade in the liver (<xref ref-type="bibr" rid="bibr1-0748233711420473">Bloom and Brandt, 2001</xref>).</p>
<p>It is important to note that the doses used in previously published studies were higher than those to which most people are likely to be exposed. <xref ref-type="bibr" rid="bibr23-0748233711420473">Oberdorster (2010</xref>) recommended that, the results of toxicological studies using extraordinarily high experimental doses should be interpreted with caution. The high toxicity at low doses which were evident in the present study may be due to the less number of nanoparticles in that mass, which may result in less agglomeration, making them to penetrate into the cells. In support to our hypothesis Zook<xref ref-type="bibr" rid="bibr35-0748233711420473"> et al. (2011</xref>) reported that large agglomerates of silver nanoparticles cause significantly less hemolytic toxicity than small agglomerates.</p>
<p>Information about toxicity of nano-enabled products combined with the knowledge of unintentional human exposure or intentional delivery for medicinal purposes must be necessary to determine real or perceived risks of nanomaterials. Hence, our results suggest that significance of dose—one of the key concepts of nanotoxicology—needs to be addressed while evaluating the toxicity of engineered nanomaterials.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0748233711420473">
<label>Conflict of interest</label>
<p>The authors declared no conflicts of interest.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0748233711420473">
<label>Funding</label>
<p>The research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bloom</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Brandt</surname>
<given-names>JT</given-names>
</name>
</person-group> (<year>2001</year>) <article-title>Toxic responses of the blood</article-title>. In: <comment>Casarette and Doull</comment> (eds) <source>Basic Science of Poison</source>. <edition>6th ed</edition>. <publisher-name>New York: Mc Graw Hill</publisher-name>.</citation>
</ref>
<ref id="bibr2-0748233711420473">
<citation citation-type="book">
<collab collab-type="author">Chemical Industry Vision 2020 technology Partnership and SRC</collab> (<year>2005</year>) <article-title>Joint NNI-ChI CBAN and SRC CWG5 Nanotechnology research needs recommendations</article-title>.</citation>
</ref>
<ref id="bibr3-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Croteau</surname>
<given-names>MN</given-names>
</name>
<name>
<surname>Dybowska</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Luoma</surname>
<given-names>SN</given-names>
</name>
<name>
<surname>Jones</surname>
<given-names>EV</given-names>
</name>
</person-group> (<year>2011</year>) <article-title>A novel approach reveals that zinc oxide nanoparticles are bioavailable and toxic after dietary exposures</article-title>. <source>Nanotoxicology</source> <volume>5</volume>(<issue>1</issue>): <fpage>79</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr4-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dufour</surname>
<given-names>EK</given-names>
</name>
<name>
<surname>Kumaravel</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nohynek</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Kirkland</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Toutain</surname>
<given-names>H</given-names>
</name>
</person-group> (<year>2006</year>) <article-title>Clastogenicity, photo-clastogenicity or pseudo-photoclastogenicity: genotoxic effects of zinc oxide in the dark, in pre-irradiated or simultaneously irradiated Chinese hamster ovary cells</article-title>. <source>Mutation Research</source> <volume>607</volume>(<issue>2</issue>): <fpage>215</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr5-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ellis</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Goldberg</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Spooner</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Ward</surname>
<given-names>MA</given-names>
</name>
</person-group> (<year>1978</year>) <article-title>Serum enzyme tests in disease of the liver and biliary tree</article-title>. <source>American Journal of Clinical Pathology</source> <volume>70</volume>(<issue>2</issue>): <fpage>248</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr6-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoet</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Gilissen</surname>
<given-names>LP</given-names>
</name>
<name>
<surname>Leyva</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nemery</surname>
<given-names>B</given-names>
</name>
</person-group> (<year>1999</year>) <article-title>In vitro cytotoxicity of textile paint components linked to the “Ardystil syndrome”</article-title>. <source>Toxicological Sciences</source> <volume>52</volume>(<issue>2</issue>): <fpage>209</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr7-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoet</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Gilissen</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Nemery</surname>
<given-names>B</given-names>
</name>
</person-group> (<year>2001</year>) <article-title>Polyanions protect against the in vitro pulmonary toxicity of polycationic paint components associated with the Ardystil syndrome</article-title>. <source>Toxicology and Applied Pharmacology</source> <volume>175</volume>(<issue>2</issue>): <fpage>184</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr8-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoshino</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fujioka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Oku</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Suga</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sasaki</surname>
<given-names>YF</given-names>
</name>
<name>
<surname>Ohta</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> (<year>2004</year>) <article-title>Physicochemical properties and cellular toxicity of nanocrystal quantum dots depend on their surface modification</article-title>. <source>Nano Letters</source> <volume>4</volume>: <fpage>2163</fpage>–<lpage>2169</lpage>.</citation>
</ref>
<ref id="bibr9-0748233711420473">
<citation citation-type="journal">
<collab collab-type="author">ICON</collab> (<year>2008</year>) <source>Predicting Nano-Biointeractions: An International Assessment of Nanotechnology Environment, Health, and Safety Research Needs</source>. <publisher-loc>Houston, TX</publisher-loc>: <publisher-name>International Council on Nanotechnology</publisher-name>.</citation>
</ref>
<ref id="bibr10-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ju-Nam</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Lead</surname>
<given-names>JR</given-names>
</name>
</person-group> (<year>2008</year>) <article-title>Manufactured nanoparticles: an overview of their chemistry, interactions and potential environmental implications</article-title>. <source>The <italic>Science of the Total Environment</italic>
</source> <volume>400</volume>(<issue>1-3</issue>): <fpage>396</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr11-0748233711420473">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Kellerman</surname>
<given-names>J</given-names>
</name>
</person-group> (<year>1995</year>) <source>Blood Test</source>. <publisher-loc>Chicago, USA</publisher-loc>: <publisher-name>Signet Book. Reprint edition</publisher-name>.</citation>
</ref>
<ref id="bibr12-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kreyling</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Semmler-Behnke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moller</surname>
<given-names>W</given-names>
</name>
</person-group> (<year>2006</year>) <article-title>Health implications of nanoparticles</article-title>. <source>Journal of Nanoparticulate Research</source> <volume>8</volume>: <fpage>543</fpage>–<lpage>562</lpage>.</citation>
</ref>
<ref id="bibr13-0748233711420473">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Luther</surname>
<given-names>W</given-names>
</name>
</person-group> (<year>2004</year>) <source>Technological Analysis. Industrial Application of Nanomaterials—Chances and Risks</source>. <publisher-loc>Düsseldorf</publisher-loc>: <publisher-name>Future Technologies division of VDI Technologiezentrum GmbH</publisher-name>.</citation>
</ref>
<ref id="bibr14-0748233711420473">
<citation citation-type="book">
<collab collab-type="author">Lux Research</collab> (<year>2009</year>) <source>Nanomaterials State of the Market Q1 2009</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Lux Research Inc</publisher-name>.</citation>
</ref>
<ref id="bibr15-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Magrez</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kasas</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Salicio</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Cellular toxicity of carbon-based nanomaterials</article-title>. <source>Nano Letters</source> <volume>6</volume>(<issue>6</issue>): <fpage>1121</fpage>–<lpage>1125</lpage>.</citation>
</ref>
<ref id="bibr16-0748233711420473">
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Maynard</surname>
<given-names>AD</given-names>
</name>
</person-group> (<year>2006</year>) <source>Nanotechnology: A Research Strategy for Addressing Risk</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>Woodrow</publisher-name>
<publisher-name> Wilson International Center</publisher-name>
<publisher-name> for Scholars, Project on Emerging Nanotechnologies</publisher-name>.</citation>
</ref>
<ref id="bibr17-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maynard</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Aitken</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Butz</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>) <article-title>Safe handling of nanotechnology</article-title>. <source>Nature</source> <volume>444</volume>(<issue>7117</issue>): <fpage>267</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr18-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maynard</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Kuempel</surname>
<given-names>ED</given-names>
</name>
</person-group> (<year>2005</year>) <article-title>Airborne nanostructured particles and occupational health</article-title>. <source>Journal of Nanoparticle Research</source> <volume>7</volume>: <fpage>587</fpage>–<lpage>614</lpage>.</citation>
</ref>
<ref id="bibr20-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Madler</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>N</given-names>
</name>
</person-group> (<year>2006</year>) <article-title>Toxic potential of materials at the nanolevel</article-title>. <source>Science</source> <volume>311</volume>(<issue>5761</issue>): <fpage>622</fpage>–<lpage>627</lpage>.</citation>
</ref>
<ref id="bibr21-0748233711420473">
<citation citation-type="journal">
<collab collab-type="author">NNI</collab> (<year>2008</year>) <source>Strategy for nanotechnology-related environmental, health and safety research</source>. <publisher-loc>Chicago, IL</publisher-loc>: <publisher-name>National Nanotechnology Initiative</publisher-name>.</citation>
</ref>
<ref id="bibr22-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oberdörster</surname>
<given-names>G</given-names>
</name>
</person-group> (<year>2000</year>) <article-title>Toxicology of ultrafine particles: in vivo studies</article-title>. <source>Philosophical Transactions of the Royal Society of London</source> <source>Series A-Mathematical Physical and Engineering Sciences</source>. <volume>358</volume>: <fpage>2719</fpage>–<lpage>2740</lpage>.</citation>
</ref>
<ref id="bibr23-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oberdorster</surname>
<given-names>G</given-names>
</name>
</person-group> (<year>2010</year>) <article-title>Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology</article-title>. <source>Journal of Internal Medicine</source> <volume>267</volume>(<issue>1</issue>): <fpage>89</fpage>–<lpage>105</lpage>.</citation>
</ref>
<ref id="bibr24-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oberdörster</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Maynard</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Donaldson</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group> (<year>2005</year>) <article-title>Principles for characterizing the potential human health effects from exposure to nanomaterials: elements of a screening strategy</article-title>. <source>Fiber Toxicology</source> <volume>2</volume>: <fpage>8</fpage>. <comment>doi:10.1186/1743-8977-2-8</comment>.</citation>
</ref>
<ref id="bibr25-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oberdorster</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Oberdorster</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Oberdorster</surname>
<given-names>J</given-names>
</name>
</person-group> (<year>2005</year>) <article-title>Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles</article-title>. <source>Environmental Health Perspectives</source> <volume>113</volume>(<issue>7</issue>): <fpage>823</fpage>–<lpage>839</lpage>.</citation>
</ref>
<ref id="bibr26-0748233711420473">
<citation citation-type="journal">
<collab collab-type="author">PCAST</collab> (<year>2010</year>) <source>Report to the President and Congress on the Third Assessment of the National nanotechnology Initiative</source>. <publisher-loc>Washington, DC</publisher-loc>: <publisher-name>President’s Council of Advisors on Science and Technology</publisher-name>.</citation>
</ref>
<ref id="bibr27-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qiang</surname>
<given-names>JL</given-names>
</name>
</person-group> (<year>2001</year>) <article-title>The surface properties and photocatalytic activities of ZnO ultrafine particles</article-title>. <source>Applied Surface Science</source> <volume>180</volume>: <fpage>308</fpage>–<lpage>314</lpage>.</citation>
</ref>
<ref id="bibr28-0748233711420473">
<citation citation-type="book">
<collab collab-type="author">RCEP</collab> (<year>2008</year>) <source>Novel Materials in the Environment: The Case of Nanotechnology</source>. <publisher-loc>London, UK</publisher-loc>: <publisher-name>Royal Commission on Environmental Pollution</publisher-name>.</citation>
</ref>
<ref id="bibr29-0748233711420473">
<citation citation-type="book">
<collab collab-type="author">SCENIHR</collab> (<year>2005</year>) <article-title>Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR): Opinion on the Appropriateness of Existing Methodologies to Assess the Potential Risks Associated with Engineered and Adventitious Products of Nanotechnologies. Scientific Committee on Emerging and newly Identified Health Risks</article-title>.</citation>
</ref>
<ref id="bibr30-0748233711420473">
<citation citation-type="book">
<collab collab-type="author">SCENIHR</collab> (<year>2009</year>) <source>Risk Assessment of Products of Nanotechnologies</source>. <publisher-loc>Brussels</publisher-loc>: <publisher-name>Scientific Committee on Emerging and Newly Identified Health Risks</publisher-name>.</citation>
</ref>
<ref id="bibr31-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Surekha</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Sairam Kishore</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Srinivas</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Selvam</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Goparaju</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Neelakanta Reddy</surname>
<given-names>P</given-names>
</name>
<etal/>
</person-group> <article-title>Repeated dose dermal toxicity study of nano zinc oxide with Sprague Dawley rats</article-title>. <source>Cutaneous and Ocular Toxicology</source> (<comment>in press</comment>).</citation>
</ref>
<ref id="bibr32-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>) <article-title>Acute toxicological impact of nano- and submicro-scaled zinc oxide powder on healthy adult mice</article-title>. <source>Journal of Nanoparticle Research</source> <volume>10</volume>: <fpage>263</fpage>–<lpage>276</lpage>.</citation>
</ref>
<ref id="bibr33-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wick</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Manser</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Limbach</surname>
<given-names>LK</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>) <article-title>The degree and kind of agglomeration affect carbon nanotube cytotoxicity</article-title>. <source>Toxicology Letters</source> <volume>168</volume>(<issue>2</issue>): <fpage>121</fpage>–<lpage>131</lpage>.</citation>
</ref>
<ref id="bibr34-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Huanga</surname>
<given-names>Q</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Synthesis of Na-doped ZnO nanowires and their photocatalytic properties</article-title>. <source>Journal of Luminescence</source> <volume>130</volume>(<issue>11</issue>): <fpage>2136</fpage>–<lpage>2141</lpage>.</citation>
</ref>
<ref id="bibr35-0748233711420473">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zook</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>MacCuspie</surname>
<given-names>RI</given-names>
</name>
<name>
<surname>Locascio</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Halter</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>JT</given-names>
</name>
</person-group> (<year>2011</year>) <article-title>Stable nanoparticle aggregates /agglomerates of different size on hemolytic cytotoxicity</article-title>. <source>Nanotoxicology</source> <comment>DOI: 10.3109/17435390.2010.536615</comment>.</citation>
</ref>
</ref-list>
</back>
</article>